Masimo (Nasdaq: MASI)+
announced today that it received FDA 510(k) clearance for expanded indications for its O3 regional oximetry technology

Tandem Diabetes Care (Nasdaq:TNDM) has a new infusion set on the way to pair with its insulin delivery offerings.